EVMT — Evome Medical Technologies Income Statement
0.000.00%
- CA$0.42m
- CA$16.47m
- CA$62.63m
- 51
- 86
- 16
- 50
Annual income statement for Evome Medical Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2019 February 28th | R2020 February 29th | 2021 February 28th | 2022 February 28th | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.26 | 0.402 | 0.15 | 18.3 | 62.6 |
Cost of Revenue | |||||
Gross Profit | 1.27 | 0.384 | — | 5.96 | 22.5 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3.6 | 1.75 | 2.82 | 28.3 | 82.3 |
Operating Profit | -2.33 | -1.35 | -2.67 | -9.96 | -19.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.33 | -1.35 | -2.67 | -4.47 | -15.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.33 | -1.35 | -2.67 | -4.37 | -15.6 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.761 | -1.92 | -2.67 | -4.37 | -15.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.761 | -1.92 | -2.67 | -4.37 | -15.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.069 | -0.037 | -0.025 | 0.039 | -0.087 |
Dividends per Share |